

## CLAIM AMENDMENTS


### Listing of Claims:

Claims 1-23 (canceled)

Claims 24-33 (canceled)

Claim 34 (not entered)

Claim 35 (new): A macrocyclic compound of the formula (1):




and its pharmaceutically acceptable salts,

wherein

Fragment A<sub>1</sub> is:


(1-i)



wherein

Y is selected from the group consisting of

{W:\06670\000H748-000\00080988.DOC \*06670000H748-000\* }




$X_1$  is  $-\text{CH}-$ ,  $-(\text{CH}_2)_2-$  or  $-(\text{CH}_2)_3-$ ;

when  $X_1$  is  $-(\text{CH}_2)_2-$  or  $-(\text{CH}_2)_3-$ ,  $R_1$  is absent;

when  $X_1$  is  $-\text{CH}-$ ,  $R_1$  is a radical independently selected from the group consisting of

{W:\06670\000H748-000\00080988.DOC \*06670000H748-000\* }




Fragment A<sub>2</sub> is:

(2-i) *D*-proline, *L*-proline, *D*-4-hydroxyproline, *L*-4-hydroxyproline, *D*-4-tert-butoxyproline, *L*-4-tert-butoxyproline; or

(2-ii)

{W:\06670\000H748-000\00080988.DOC \*06670000H748-000\* }




wherein

$X_2$  is  $-\text{CH}-$ ,  $-(\text{CH}_2)_2-$  or  $-(\text{CH}_2)_3-$ ;

when  $X_2$  is  $-(\text{CH}_2)_2-$  or  $-(\text{CH}_2)_3-$ ,  $R_2$  is absent;

when  $X_2$  is  $-\text{CH}-$ ,  $R_2$  is a radical independently selected from the group consisting of




Fragment A<sub>3</sub> is:

(3-i) *D*-proline, *L*-proline, *D*-4-hydroxyproline, *L*-4-hydroxyproline, *D*-4-tert-butoxyproline, *L*-4-tert-butoxyproline; or

(3-ii)

{W:\06670\000H748-000\00080988.DOC \*06670000H748-000\* }




wherein

$X_3$  is  $-\text{CH}-$ ,  $-(\text{CH}_2)_2-$  or  $-(\text{CH}_2)_3-$ ;

when  $X_3$  is  $-(\text{CH}_2)_2-$  or  $-(\text{CH}_2)_3-$ ,  $R_3$  is absent;

when  $X_3$  is  $-\text{CH}-$ ,  $R_3$  is a radical independently selected from the group consisting of






wherein (N) indicates the site of a covalent bond to the nitrogen atom of A<sub>1</sub> of formula (1) and (C) indicates the site of a covalent bond to the carbonyl carbon of A<sub>3</sub> of formula (1).

Claim 36 (new): A macrocyclic compound of the formula (1):

{W:\06670\000H748-000\00080988.DOC \*06670000H748-000\* }






and its pharmaceutically acceptable salts,

wherein


Fragment A<sub>1</sub> is:

(1-i)



wherein

Y is selected from the group consisting of




X<sub>1</sub> is -CH-, -(CH<sub>2</sub>)<sub>2</sub>- or -(CH<sub>2</sub>)<sub>3</sub>-;

when X<sub>1</sub> is -(CH<sub>2</sub>)<sub>2</sub>- or -(CH<sub>2</sub>)<sub>3</sub>-, R<sub>1</sub> is absent;

{W:\06670\000H748-000\00080988.DOC \*06670000H748-000\* }

when  $X_1$  is  $-\text{CH}-$ ,  $R_1$  is a radical independently selected from the group consisting of




Fragment  $A_2$  is:

{W:\06670\000H748-000\00080988.DOC \*06670000H748-000\* }

(2-i) *D*-proline, *L*-proline, *D*-4-hydroxyproline, *L*-4-hydroxyproline, *D*-4-tert-butoxyproline, *L*-4-tert-butoxyproline; or

(2-ii)




wherein

X<sub>2</sub> is -CH-, -(CH<sub>2</sub>)<sub>2</sub>- or -(CH<sub>2</sub>)<sub>3</sub>-;

when X<sub>2</sub> is -(CH<sub>2</sub>)<sub>2</sub>- or -(CH<sub>2</sub>)<sub>3</sub>-, R<sub>2</sub> is absent;

when X<sub>2</sub> is -CH-, R<sub>2</sub> is a radical independently selected from the group consisting of




Fragment A<sub>3</sub> is:

(3-i) *D*-proline, *L*-proline, *D*-4-hydroxyproline, *L*-4-hydroxyproline, *D*-4-tert-butoxyproline, *L*-4-tert-butoxyproline; or

(3-ii)

{W:\06670\000H748-000\00080988.DOC \*06670000H748-000\* }




wherein

$X_3$  is  $-\text{CH}-$ ,  $-(\text{CH}_2)_2-$  or  $-(\text{CH}_2)_3-$ ;


when  $X_3$  is  $-(\text{CH}_2)_2-$  or  $-(\text{CH}_2)_3-$ ,  $R_3$  is absent;

when  $X_3$  is  $-\text{CH}-$ ,  $R_3$  is a radical independently selected from the group consisting of




$W_1$  to  $W_{16}$  are each selected from the group consisting of hydrogen and a compatible protecting group chosen from:

{W:\06670\000H748-000\00080988.DOC \*06670000H748-000\* }



Fragment T is a radical selected from the group consisting of:


{W:\06670\000H748-000\00080988.DOC \*06670000H748-000\* }



Claim 37 (new): A macrocyclic compound of the formula (1):

{W:\06670\000H748-000\00080988.DOC \*06670000H748-000\* }






and it's pharmaceutically acceptable salts,

wherein

Fragment A<sub>1</sub> is:

(1-i)



wherein


X<sub>1</sub> is -CH-, -(CH<sub>2</sub>)<sub>2</sub>- or -(CH<sub>2</sub>)<sub>3</sub>-;

when X<sub>1</sub> is -(CH<sub>2</sub>)<sub>2</sub>- or -(CH<sub>2</sub>)<sub>3</sub>-, R<sub>1</sub> is absent;

when X<sub>1</sub> is -CH-, R<sub>1</sub> is a radical independently selected from the group consisting of:

{W:\06670\000H748-000\00080988.DOC \*06670000H748-000\* }







wherein

$X_2$  is  $-CH-$ ,  $-(CH_2)_2-$  or  $-(CH_2)_3-$ ;

when  $X_2$  is  $-(CH_2)_2-$  or  $-(CH_2)_3-$ ,  $R_2$  is absent;

when  $X_2$  is  $-CH-$ ,  $R_2$  is a radical independently selected from the group consisting of






wherein

$X_3$  is  $-\text{CH}-$ ,  $-(\text{CH}_2)_2-$  or  $-(\text{CH}_2)_3-$ ;


when  $X_3$  is  $-(\text{CH}_2)_2-$  or  $-(\text{CH}_2)_3-$ ,  $\text{R}_3$  is absent;

when  $X_3$  is  $-\text{CH}-$ ,  $\text{R}_3$  is a radical independently selected from the group consisting of



Fragment T is a radical selected from the group consisting of:

{W:\06670\000H748-000\00080988.DOC \*06670000H748-000\* }



wherein (N) indicates the site of a covalent bond to the nitrogen atom of A<sub>1</sub> of formula (1) and (C) indicates the site of a covalent bond to the carbonyl carbon of A<sub>3</sub> of formula (1).

{W:\06670\000H748-000\00080988.DOC \*06670000H748-000\* }